The Use of Positron Emission Tomography (PET) in the Staging/Evaluation, Treatment, and Follow-Up of Patients With Lung Cancer: A Critical Review

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 5, 2008, Pages 1298-1306

  Mac Manus, Michael ^a   Hicks, Rodney J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Lung cancer; Position emission tomography; Radiation therapy; Surgery

Indexed keywords

FLUORODEOXYGLUCOSE;

ADRENAL METASTASIS; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; INTESTINE CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDIASTINOSCOPY; MEDIASTINUM CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MEDIASTINOSCOPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 56349094773     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.08.022     Document Type: Review

References (55)

1. Siegel B.A., and Dehdashti F. Oncologic PET/CT: Current status and controversies. Eur Radiol 15 Suppl 4 (2005) D127-D132
2. Freudenberg L.S., Rosenbaum S.J., Beyer T., et al. PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Radiol Clin North Am 45 (2007) 639-644 v
3. Chen W., Cloughesy T., Kamdar N., et al. Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med 46 (2005) 945-952
4. Rajendran J.G., and Krohn K.A. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 43 (2005) 169-187
5. Park S.J., Ionascu D., Killoran J., et al. Evaluation of the combined effects of target size, respiratory motion and background activity on 3D and 4D PET/CT images. Phys Med Biol 53 (2008) 3661-3679
6. Berghmans T., Dusart M., Paesmans M., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): A systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3 (2008) 6-12
7. Gould M.K., Maclean C.C., Kuschner W.G., et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA 285 (2001) 914-924
8. Nomori H., Watanabe K., Ohtsuka T., et al. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. Ann Thorac Surg 79 (2005) 984-988 discussion 989
9. Toloza E.M., Harpole L., and McCrory D.C. Noninvasive staging of non-small cell lung cancer: A review of the current evidence. Chest 123 (2003) 137S-146S
10. Dwamena B.A., Sonnad S.S., Angobaldo J.O., et al. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 213 (1999) 530-536
11. Gould M.K., Kuschner W.G., Rydzak C.E., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis. Ann Intern Med 139 (2003) 879-892
12. Hellwig D., Ukena D., Paulsen F., et al. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000]. Pneumologie 55 (2001) 367-377
13. Silvestri G.A., Gould M.K., Margolis M.L., et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 132 (2007) 178S-201S
14. Kernstine K.H., McLaughlin K.A., Menda Y., et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?. Ann Thorac Surg 73 (2002) 394-401 discussion 401-392
15. Reed C.E., Harpole D.H., Posther K.E., et al. Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126 (2003) 1943-1951
16. Graeter T.P., Hellwig D., Hoffmann K., et al. Mediastinal lymph node staging in suspected lung cancer: Comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 75 (2003) 231-235 discussion 235-236
17. van Tinteren H., Hoekstra O.S., Smit E.F., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial. Lancet 359 (2002) 1388-1393
18. Viney R.C., Boyer M.J., King M.T., et al. Randomized controlled trial of the role of positron emission tomography in the management of Stage I and II non-small-cell lung cancer. J Clin Oncol 22 (2004) 2357-2362
19. Marom E.M., McAdams H.P., Erasmus J.J., et al. Staging non-small cell lung cancer with whole-body PET. Radiology 212 (1999) 803-809
20. Yun M., Kim W., Alnafisi N., et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42 (2001) 1795-1799
21. MacManus M.P., Hicks R.J., Matthews J.P., et al. High rate of detection of unsuspected distant metastases by pet in apparent Stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 287-293
22. MacManus M.R., Hicks R., Fisher R., et al. FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy-survival correlates with metastatic disease burden. Acta Oncol 42 (2003) 48-54
23. Eschmann S.M., Friedel G., Paulsen F., et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 29 (2002) 804-808
24. Marom E.M., Bruzzi J.F., and Truong M.T. Extrathoracic PET/CT findings in thoracic malignancies. J Thorac Imaging 21 (2006) 154-166
25. Mac Manus M.P., Hicks R.J., Ball D.L., et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: Powerful correlation with survival and high impact on treatment. Cancer 92 (2001) 886-895
26. Mac Manus M.P., Wong K., Hicks R.J., et al. Early mortality after radical radiotherapy for non-small-cell lung cancer: Comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 52 (2002) 351-361
27. Kiffer J.D., Berlangieri S.U., Scott A.M., et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 19 (1998) 167-177
28. Munley M.T., Marks L.B., Scarfone C., et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 23 (1999) 105-114
29. Nestle U., Walter K., Schmidt S., et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44 (1999) 593-597
30. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55 (2000) 317-324
31. Giraud P., De Rycke Y., Minet P., et al. [Estimation of the probability of mediastinal involvement: A statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy in non-small-cell lung cancer?]. Cancer Radiother 5 (2001) 725-736
32. Caldwell C.B., Mah K., Ung Y.C., et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: The impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 51 (2001) 923-931
33. Mah K., Caldwell C.B., Ung Y.C., et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: A prospective study. Int J Radiat Oncol Biol Phys 52 (2002) 339-350
34. Erdi Y.E., Rosenzweig K., Erdi A.K., et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62 (2002) 51-60
35. Bradley J., Thorstad W.L., Mutic S., et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 59 (2004) 78-86
36. Messa C., Ceresoli G.L., Rizzo G., et al. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer. Q J Nucl Med Mol Imaging 49 (2005) 259-266
37. van Der Wel A., Nijsten S., Hochstenbag M., et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: A modeling study. Int J Radiat Oncol Biol Phys 61 (2005) 649-655
38. Ashamalla H., Rafla S., Parikh K., et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1016-1023
39. Deniaud-Alexandre E., Touboul E., Lerouge D., et al. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1432-1441
40. Remonnay R., Morelle M., Pommier P., et al. Assessing short-term effects and costs at an early stage of innovation: The use of positron emission tomography on radiotherapy treatment decision making. Int J Technol Assess Health Care 24 (2008) 212-220
41. van Baardwijk A., Bosmans G., Boersma L., et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 68 (2007) 771-778
42. Nestle U., Kremp S., Schaefer-Schuler A., et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 46 (2005) 1342-1348
43. Stroom J., Blaauwgeers H., van Baardwijk A., et al. Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. Int J Radiat Oncol Biol Phys 69 (2007) 267-275
44. Werner-Wasik M., Xiao Y., Pequignot E., et al. Assessment of lung cancer response after nonoperative therapy: Tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 51 (2001) 56-61
45. Lever A.M., Henderson D., Ellis D.A., et al. Radiation fibrosis mimicking local recurrence in small cell carcinoma of the bronchus. Br J Radiol 57 (1984) 178-180
46. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to CT scanning for response-assessment after radical radiotherapy/chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 21 (2003) 1285-1292
47. Bury T., Corhay J.L., Duysinx B., et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 14 (1999) 1376-1380
48. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 49 (2005) 95-108
49. Hicks R.J., Mac Manus M.P., Matthews J.P., et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: Inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60 (2004) 412-418
50. Akhurst T., Downey R.J., Ginsberg M.S., et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 73 (2002) 259-264 discussion 264-266
51. Choi N.C., Fischman A.J., Niemierko A., et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54 (2002) 1024-1035
52. Dooms C., Verbeken E., Stroobants S., et al. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: A model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 26 (2008) 1128-1134
53. Hoekstra C.J., Hoekstra O.S., Stroobants S.G., et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43 (2002) 1304-1309
54. Kong F.M., Frey K.A., Quint L.E., et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 25 (2007) 3116-3123
55. Hicks R.J., Kalff V., MacManus M.P., et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 42 (2001) 1605-1613